Literature DB >> 35657614

Development and characterization of a mass cytometry panel for detecting the effect of acute doxorubicin exposure on murine cardiac nonmyocytes.

Brian S Iskra1,2,3, Logan Davis3, Henry E Miller2,3, Yu-Chiao Chiu3,4, Alexander J R Bishop2,3, Yidong Chen2,3,4, Gregory J Aune2,3,5.   

Abstract

Childhood cancer survivors (CCSs) face lifelong side effects related to their treatment with chemotherapy. Anthracycline agents, such as doxorubicin (DOX), are important in the treatment of childhood cancers but are associated with cardiotoxicity. Cardiac toxicities represent a significant source of chronic disability that cancer survivors face; despite this, the chronic cardiotoxicity phenotype and how it relates to acute toxicity remains poorly defined. To address this critical knowledge gap, we studied the acute effect of DOX on murine cardiac nonmyocytes in vivo. Determination of the acute cellular effects of DOX on nonmyocytes, a cell pool with finite replicative capacity, provides a basis for understanding the pathogenesis of the chronic heart disease that CCSs face. To investigate the acute cellular effects of DOX, we present single-cell RNA sequencing (scRNAseq) data from homeostatic cardiac nonmyocytes and compare it with preexisting datasets, as well as a novel CyTOF datasets. SCANPY, a python-based single-cell analysis, was used to assess the heterogeneity of cells detected in scRNAseq and CyTOF. To further assist in CyTOF data annotation, joint analyses of scRNAseq and CyTOF data using an artificial neural network known as sparse autoencoder for clustering, imputation, and embedding (SAUCIE) are performed. Lastly, the panel is tested on a mouse model of acute DOX exposure at two time points (24 and 72 h) after the last dose of doxorubicin and examined with joint clustering. In sum, we report the first ever CyTOF study of cardiac nonmyocytes and characterize the effect of acute DOX exposure with scRNAseq and CyTOF.NEW & NOTEWORTHY We describe the first mass cytometry studies of murine cardiac nonmyocytes. The mass cytometry panel is compared with single-cell RNA sequencing data. Homeostatic cardiac nonmyocytes are characterized by mass cytometry to identify and quantify four major cell populations: endothelial cells, fibroblasts, leukocytes, and pericytes. The single-cell acute nonmyocyte response to doxorubicin is studied at 24 and 72 h after doxorubicin exposure given daily for 5 days at a dose of 4 mg/kg/day.

Entities:  

Keywords:  anthracyclines; cardiotoxicity; nonmyocytes; single cell

Mesh:

Substances:

Year:  2022        PMID: 35657614      PMCID: PMC9236860          DOI: 10.1152/ajpheart.00514.2021

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  25 in total

Review 1.  Identifying cell populations with scRNASeq.

Authors:  Tallulah S Andrews; Martin Hemberg
Journal:  Mol Aspects Med       Date:  2017-07-25

2.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

Review 3.  Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.

Authors:  Saro H Armenian; Gregory T Armstrong; Gregory Aune; Eric J Chow; Matthew J Ehrhardt; Bonnie Ky; Javid Moslehi; Daniel A Mulrooney; Paul C Nathan; Thomas D Ryan; Helena J van der Pal; Elvira C van Dalen; Leontien C M Kremer
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

4.  Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury.

Authors:  Nona Farbehi; Ralph Patrick; Aude Dorison; Munira Xaymardan; Vaibhao Janbandhu; Katharina Wystub-Lis; Joshua Wk Ho; Robert E Nordon; Richard P Harvey
Journal:  Elife       Date:  2019-03-26       Impact factor: 8.140

5.  Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity.

Authors:  Fei Wang; Brian Iskra; Eugenie Kleinerman; Claudia Alvarez-Florez; Thomas Andrews; Angela Shaw; Joya Chandra; Keri Schadler; Gregory J Aune
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

6.  Proliferative potential of human fibroblasts: an inverse dependence on cell size.

Authors:  J C Angello; W R Pendergrass; T H Norwood; J Prothero
Journal:  J Cell Physiol       Date:  1987-07       Impact factor: 6.384

7.  Recovering Gene Interactions from Single-Cell Data Using Data Diffusion.

Authors:  David van Dijk; Roshan Sharma; Juozas Nainys; Kristina Yim; Pooja Kathail; Ambrose J Carr; Cassandra Burdziak; Kevin R Moon; Christine L Chaffer; Diwakar Pattabiraman; Brian Bierie; Linas Mazutis; Guy Wolf; Smita Krishnaswamy; Dana Pe'er
Journal:  Cell       Date:  2018-06-28       Impact factor: 41.582

8.  SCANPY: large-scale single-cell gene expression data analysis.

Authors:  F Alexander Wolf; Philipp Angerer; Fabian J Theis
Journal:  Genome Biol       Date:  2018-02-06       Impact factor: 13.583

9.  flowCore: a Bioconductor package for high throughput flow cytometry.

Authors:  Florian Hahne; Nolwenn LeMeur; Ryan R Brinkman; Byron Ellis; Perry Haaland; Deepayan Sarkar; Josef Spidlen; Errol Strain; Robert Gentleman
Journal:  BMC Bioinformatics       Date:  2009-04-09       Impact factor: 3.169

10.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.